Introduction
============

Over the past few decades, the rate of obesity has risen three-fold and is more than 30% in some European countries[@R1]. Around 50% of all adults in Europe are classified as overweight[@R2],[@R3]. Obesity has become a global epidemic that affects diverse societies across developed and developing countries[@R4]. Obesity rates correlate well with recent developments such as incessant enticements to sit and an unprecedented availability, at low or no cost, of foods and beverages rich in poorly satiating calories[@R5]. These rapid environmental changes interact with preexisting genetic tendencies, yet in a timescale so brief as to outstrip evolution[@R6]. Obesity increases the risk of hypertension, diabetes, and atherosclerosis, all risk factors for the leading cause of death worldwide---cardiovascular disease[@R7],[@R8]. Moreover, obesity is associated with a reduced quality of life[@R9],[@R10].

However, weight loss is never an easy goal to achieve or maintain. Although numerous randomized trials of lifestyle modification, medications, and bariatric surgery have shown that weight loss reduces morbidity, most patients cannot sustain sufficient weight loss[@R11]. Lifestyle modifications, restricted-calorie diet and increased physical activity, are easily operated but hardly endurable. Few safe and effective drugs are currently available for the treatment of obesity because of side effects and inadequate efficacy, especially in the long term. Bariatric surgery results in the most weight loss and the highest rates of remission of type 2 diabetes, but the potential side effects are of concern[@R12]. Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue with a 97% structural homology to human GLP-1, a gut-derived incretin hormone has been shown to improve glucose tolerance and lose weight in individuals with type 2 diabetes (T2DM)[@R13]. This provided a rationale for investigating liraglutide as a treatment for obese, non-diabetic individuals.

Only a few clinical studies have demonstrated the effect of liraglutide action in obese, non-diabetic individuals. To date, no meta-analysis of liraglutide\'s safety and efficacy in individuals without diabetes has been conducted. The goal of the present study was toerform a meta-analysis to evaluate the efficacy and safety of liraglutide in obese, non-diabetic individuals.

Materials and methods
=====================

Search strategy
---------------

All randomized controlled trials reporting the effect of liraglutide in weight management for obese, non-diabetic individuals were systematically searched in the Medline, Embase and Cochrane Controlled Trials Register databases until May 2018. The search strategy was designed to identify all possible studies that included the following key words: "liraglutide" AND "weight loss" AND "non-diabetic" AND "randomized controlled trial". All related studies published in English language were included. In addition, a manual search was conducted to investigate the relevant references of the retrieved publications. 2.2. Inclusion criteria, trial selection, exclusion criteria and data extraction

All the selected articles were screened according to the following criteria for inclusion: (1) The study design included treatment with liraglutide for obese, non-diabetic individuals; (2) the study provided accurate data that could be analyzed, including the total number of subjects and the values of each index; and (3) the full text of the study could be accessed. If the same author reported various articles sharing the identical case series, only the study with the most persons was used, and if the same research was published in different journals, only the most recent article was included for analysis. Exclusion criteria were as follows: (1) not randomized controlled trial; (2) case reports, reviews, or meta-analysis; (3)studies that were based on incomplete raw data. A flow diagram of the study selection process is presented in [Figure 1](#F1){ref-type="fig"}. Two investigators retrieved data from the literature based on the same inclusion standards and then performed a crosscheck. Any disagreement was resolved by discussion or by a third investigator. Usable information was collected from each study: (1) the name of the first author and the publication year; (2) the study design and sample size; (3) the therapy that the patients received; (4) the country in which the study was conducted; and (5) data including the mean weight loss, the proportion of lost more than 5% of body weight, systolic blood pressure (SBP) decreased, the proportion of individuals who withdrawn due to adverse event (AE) and nausea.
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Quality assessment
------------------

### Data extraction

Risk of bias was rated per outcome according to Cochrane guidelines[@R14] and is summarised in [Fig. 1](#F1){ref-type="fig"}. The majority of studies were rated as low risk of bias arising from randomisation; having adequate random sequence generation and allocation concealment and few baseline imbalances. There was generally low risk of bias due to deviations from intended interventions

### Statistical analysis and meta-analysis

Relevant data recruited in the meta-analysis were compared by using RevMan v.5.1.0. (Cochrane Collaboration, Oxford, UK)[@R14]. The mean weight loss, the proportion of lost more than 5% of body weight and SBP decreased were determined as differences between baseline (study entry) and study completion. We used the fixed effects model (Mantel-Haenszel method) and random effects model (DerSimonian and Laird method) to evaluate the mean difference (MD) for continuous data and the relative risk for dichotomous results pooled across studies with corresponding 95% confidence interval (CI)[@R15]. The study was considered to be homogeneous only when the analysis showed p \> 0.05 and then a fixed-effect model was chosen for meta-analysis; otherwise, a random-effect model was more appropriate. Inconsistency across studies was quantified by I^2^ statistic, which describes the true extent of heterogeneity but not due to chance in results 16. I^2^ values range from 0 to 100%, it represents a low level of heterogeneity if I^2^ \<25%, and a significant inconsistency existing if I^2^ \>50%.

Results
=======

Characteristics of the individual studies
-----------------------------------------

The database search found 285 articles that could have been included in our meta-analysis. Based on the inclusion and exclusion criteria, 246 articles were excluded after reading the titles and abstracts of the articles. 34 articles were not randomized controlled trials. In all, 5 articles[@R17]--[@R21], reporting data from a total of 5 RCTs that compared liraglutide with placebo, were included in the analysis ([Fig. 2](#F2){ref-type="fig"}). The relevant information about the included articles is listed in [Table 1](#T1){ref-type="table"}.
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###### 

Study and patient characteristics

  -------------------------------------------------------------------------------------------------------------------------------------------------
  Study              Therapy in\   Therapy\   Country     Sample size   Administration\   Duration\      Dosage\    Inclusion\   
                     experiment\   in\                                  method            of\            (mg)       population   
                     al group      control\                                               treatment                              
                                   group                                                                                         
  ------------------ ------------- ---------- ----------- ------------- ----------------- -------------- ---------- ------------ ------------------
  Astrup A 2009\     Liraglutide   Placebo    19 sites\   93            98                subcutaneous   20 weeks   3            aged 18--65\
  \[[@R17]\]                                  in Europe                                                                          years, with\
                                                                                                                                 BMI of 30--40\
                                                                                                                                 kg/m^2^, stable\
                                                                                                                                 body weight\
                                                                                                                                 and fasting\
                                                                                                                                 plasma\
                                                                                                                                 glucose of less\
                                                                                                                                 than 7 mmol/L

  Kim SH 2013\       Liraglutide   Placebo    US          24            27                subcutaneous   14 weeks   3            aged 40--70\
  \[[@R18]\]                                                                                                                     years, with\
                                                                                                                                 BMI of 27--40\
                                                                                                                                 kg/m^2^ with\
                                                                                                                                 prediabetes

  Wadden TA\         Liraglutide   Placebo    US and\     212           210               subcutaneous   56 weeks   3            aged ≥ 18\
  2013 \[[@R19]\]                             Canada                                                                             years, with\
                                                                                                                                 stable body\
                                                                                                                                 weight and\
                                                                                                                                 BMI≥30kg/m^2^

  Pi-Sunyer X\       Liraglutide   Placebo    Europe,\    2487          1244              subcutaneous   56 weeks   3            aged ≥ 18\
  2015 \[[@R20]\]                             North\                                                                             years, with\
                                              America,\                                                                          stable body\
                                              South\                                                                             weight and\
                                              America,\                                                                          BMI≥30kg/m^2^
                                              Asia,\                                                                             
                                              Africa,\                                                                           
                                              and\                                                                               
                                              Australia                                                                          

  Blackman A 2016\   Liraglutide   Placebo    US and\     180           179               subcutaneous   32 weeks   3            aged 18--64\
  \[[@R21]\]                                  Canada                                                                             years, with\
                                                                                                                                 stable body\
                                                                                                                                 weight and\
                                                                                                                                 BMI≥30kg/m^2^
  -------------------------------------------------------------------------------------------------------------------------------------------------

BMI: body-mass index

Quality of the individual studies
---------------------------------

One study performed ITT analysis. Each included a power calculation to determine the optimal sample size ([Table 2](#T2){ref-type="table"}). The funnel plot provided a qualitative estimation of publication bias of the studies, and no evidence of bias was found ([Fig. 3](#F3){ref-type="fig"}).

###### 

Quality assessment of individual study

  ----------------------------------------------------------------------------------------------------------------------------------------
  Study                      Allocation\           Allocation\   Blinding   Loss to\    Calculation\   Statistical\   ITT\       Level\
                             sequence generation   concealment              follow-up   of sample\     analysis       analysis   of\
                                                                                        size                                     quality
  -------------------------- --------------------- ------------- ---------- ----------- -------------- -------------- ---------- ---------
  Astrup A 2009 \[[@R17]\]   A                     A             A          0           YES            Analysis of\   YES        A
                                                                                                       covariance                

  Kim SH 2013 \[[@R18]\]     B                     A             A          0           YES            t test\        NO         B
                                                                                                       or x^2^ test              

  Wadden TA\                 A                     A             A          25          YES            Analysis of\   NO         B
  2013 \[[@R19]\]                                                                                      covariance                

  Pi-Sunyer X\               A                     A             A          Not\        YES            Analysis of\   NO         B
  2015 \[[@R20]\]                                                           mention                    covariance                

  Blackman A 2016\           A                     A             A          7           YES            Analysis of\   NO         B
  \[[@R21]\]                                                                                           covariance                
  ----------------------------------------------------------------------------------------------------------------------------------------

A - all quality criteria met (adequate): low risk of bias.

B - one or more of the quality criteria only partly met (unclear): moderate risk of bias.

C - one or more criteria not met (inadequate or not used): high risk of bias.
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Liraglutide versus placebo
--------------------------

### Mean weight loss

Five RCTs, representing 4,754 participants (2,996 in the liraglutide group and 1,758 in the placebo group) ([Fig. 4](#F4){ref-type="fig"}) were identified. According to our analysis, no heterogeneity was found among the trials ([Fig. 4](#F4){ref-type="fig"}), thus a fixed-effects model was thus chosen for the analysis. Based on our analysis, the pooled estimate of MD was -5.52, and the 95% CI was -5.93 to -5.51 (p\<0.00001). This result suggests that liraglutide showed statistically significantly greater reduces in the mean weight loss compared with placebo.
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### Lost more than 5% of body weight

The four RCTs included the proportion of lost more than 5% of body weight data representing 4,395 participants (2,816 in the liraglutide group and 1,579 in the placebo group) ([Fig. 4](#F4){ref-type="fig"}). The heterogeneity test showed P=0.03, so we adopted the random-effects model ([Fig. 4](#F4){ref-type="fig"}), the OR was 5.46, and the 95% CI was 3.57 to 8.34 (p\<0.00001). This result suggests that liraglutide showed statistically significantly greater decreases in the proportion of lost more than 5% of body weight compared with placebo.

### SBP

Five RCTs included the SBP data representing a cohort of 4,754 participants (2,996 in the liraglutide group and 1,758 in the placebo group) ([Fig. 4](#F4){ref-type="fig"}). The fixed-effects estimate of the MD was -2.56, and the 95% CI was -3.28 to -1.84 (p\<0.00001). This result suggests that liraglutide had significantly greater reduces in SBP.

### Withdrawn due to AE

Four RCTs included the proportion of individuals who withdrawn due to AE data representing a cohort of 4,703 participants (2,972 in the liraglutide group and 1,731 in the placebo group) ([Fig. 5](#F5){ref-type="fig"}). The random-effects estimate of the OR was 2.85, and the 95% CI was 0.84 to 9.62 (p=0.09). The result suggests that liraglutide and placebo were similar in terms of the incidence of withdrawn due to AE.

![](AFHS1903-2591Fig5){#F5}

### Nausea

Four RCTs included the nausea data representing a cohort of 4,703 participants (2,972 in the liraglutide group and 1,731 in the placebo group) ([Fig. 5](#F5){ref-type="fig"}). The heterogeneity test showed P\<0.05, so we adopted the random-effects model ([Fig. 5](#F5){ref-type="fig"}), the OR was 5.04, and the 95% CI was 3.34 to 7.6 (p\<0.00001). The result suggests that nausea was more common among those patients treated with liraglutide as compared to those treated with placebo.

Discussion
==========

According to the data retrieved from five RCTs of at least 12 weeks of consistent therapy, our systematic review and quantitative meta-analysis summarizes the evidence regarding the efficacy and safety of liraglutide for the treatment of obese in non-diabetic individuals. This study reveals that liraglutide 3.0 mg once daily is superior to placebo in reducing weight and the proportion of lost more than 5% of body weight and SBP.

Liraglutide treatment was associated with reductions in SBP which is a cardiometabolic risk factor. Four of the included RCTs demonstrated that there were statistically significant, although sometimes quantitatively modest, improvements in glycemic control, fasting insulin concentrations, cardiometabolic markers, and quality of life measures. Besides, Pi Sunyer et al. testified the prevalence of prediabetes was significantly lower in the liraglutide group than in the placebo group at week 56, a finding that was consistent with the improvement in glycemic control with liraglutide. T2DM developed in much less patients in the liraglutide group than in the placebo group during the course of treatment[@R20].

Obesity once indicated prosperity and was considered to be attractive. But now we know that overnutrition and underexertion beget a cluster of seemingly unrelated problems labeled "the metabolic syndrome," which includes visceral abdominal obesity, dyslipoproteinemia, dysglycemia, or hypertension. Although obesity is associated with resistance to the plasma glucose lowering actions of insulin, many other metabolic pathways still remain responsive to insulin[@R22]. Liraglutide is a GLP-1 analogue which is approved for the treatment of T2DM at doses up to 1.8 mg once daily[@R13]. Weight loss with liraglutide is dose-dependent up to 3.0 mg once daily and is mediated by reduced appetite and energy intake rather than by increased energy expenditure[@R23].

The underlying mechanisms that mediate the effects of weight loss of liraglutide are most probably a combination of effects on the gastrointestinal tract and brain. Native GLP-1 has a short elimination half-life of 1--2 min, whereas liraglutide has a long half-life of about 13h and can be administered once a day by subcutaneous injection. Native GLP-1 suppresses appetite and energy intake in both normal-weight and obese individuals, and delays gastric emptying[@R24]. GLP-1 receptors are expressed in several brainstem nuclei involved in appetite regulation, and subcutaneously administered liraglutide might also reach these sites[@R25]. Can J van et al. did a RCT which demonstrated that liraglutide-induced weight loss appears to be mediated by reduced appetite and energy intake rather than increased energy expenditure[@R23].

Safety data from the trials in this meta-analysis suggest that liraglutide administration was generally well-tolerated. Although the proportion of women who experienced an AE such as nausea were significantly more frequent with liraglutide use than with placebo, they were mostly mild or moderate in severity and discontinuation due to AEs occurred no more frequently with liraglutide use than with placebo. The most commonly reported treatment emergent AEs were gastrointestinal system, but they were all well-tolerated. All of the included RCTs indicated no clinically significant changes in laboratory tests or electrocardiograms in the liraglutide groups. In a word, liraglutide 3.0 mg mg once daily subcutaneously appears to provide a good balance between efficacy and side effects. Besides, Astrup A et al. conducted a 2-year open-label extension study demonstrated that liraglutide was well tolerated, sustains weight loss over 2 years and improves cardiovascular risk factors[@R26].

The meta-analysis included the studies that all data derived from randomized double-blind, placebo-controlled trials. According to the quality-assessment scale, we conformed the quality of each study recruited in our analysis. Some limitations of the study should be mentioned. First, the number of included articles was not many. Second, the article didn\'t research the safety, efficacy of liraglutide with longer term. Finally, we didn\'t include unpublished studies. A bias may have occurred resulting from these limitations. Larger samples and more high-quality trials are needed to further investigate the efficacy and safety of liraglutide in obese, non-diabetic individuals.

Conclusion
==========

This meta-analysis indicates that liraglutide to be an effective and safe treatment for obese, non-diabetic individuals.
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